share_log

BioCryst Pharmaceuticals shares are trading higher ahead of the company's expected phase 1 clinical trial data for BCX9930.

Benzinga ·  Mar 22, 2021 19:50
BioCryst Pharmaceuticals shares are trading higher ahead of the company's expected phase 1 clinical trial data for BCX9930.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment